More Articles Back to Article
- Nivolumab gains NICE backing for rare gastroesophageal cancers
- Novartis, MMV to test new malaria drug combo in late-stage trial
- ENCell, Polyplus partner to lower viral vector production costs
- Blood-thinning drug may be harmful post-COVID-19
- Priority Review granted to BLA for tetravalent dengue vaccine
Nivolumab gains NICE backing for rare gastroesophageal cancers
The UK's National Institute of Health and Care Excellence has recommended Bristol Myers Squibb's Opdivo, or nivolumab, as a first-line treatment, combined with chemotherapy, to treat rare forms of advanced gastroesophageal cancer such as untreated HER2-negative, advanced or metastatic gastric, gastro-oesophageal junction or oesophageal adenocarcinoma if the tumors express PD-L1 with combined positive scores of five or greater. The recommendation was based on clinical results of the CheckMate-649 trial that showed use of Opdivo, combined with CapeOX or FOLFOX chemotherapy, resulted in substantial improvements in progression-free and overall survival. PMLive (UK) (11/25)
Read full article now.
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!